查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1860231

妇科癌症药物市场按最终用户、分销管道、给药途径、药物类别和癌症类型划分－2025-2032年全球预测

Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，妇科癌症治疗市场将成长至 266.3 亿美元，复合年增长率为 12.53%。

关键市场统计数据
基准年 2024 103.5亿美元
预计年份：2025年 116.3亿美元
预测年份 2032 266.3亿美元
复合年增长率 (%) 12.53%

权威的导论概述了妇科肿瘤治疗领域不断变化的格局、关键的临床挑战、创新动力以及相关人员的期望。

当今妇科肿瘤治疗领域的特点是科学创新日新月异、监管重点不断变化以及医疗服务模式的演进，这些都影响着治疗方案的研发、采购和实施。标靶治疗、免疫肿瘤药物以及更人性化的剂型等方面的最新进展正在重塑临床决策。同时，医疗系统和支付方越来越重视治疗价值、真实世界的治疗效果以及公平的医疗服务取得。在此背景下，从临床团队到供应链管理人员的相关人员必须在临床疗效、营运可行性和报销限制之间取得平衡。

分析重塑妇科癌症药物研发、商业策略、监管路径和临床应用的变革性转变

妇科肿瘤领域的变革性变化源自于技术、临床和商业性趋势的融合，这些趋势共同重塑了研发重点和医疗服务模式。精准医疗正从概念走向核心实践，基因组分析和伴随诊断指导着标靶治疗和PARP抑制剂的选择，并重新定义了临床试验设计和标籤策略。同时，免疫疗法的研究成果正被转化为联合治疗和维持治疗方案，这需要进行长期安全性监测并采用新的终点指标。这些科学进步促使申办方进行综合研发项目，以满足监管证据要求和真实世界疗效指标。

2025年美国关税的累积影响：对妇科肿瘤供应链、药品价格、临床应用和研究的连锁反应

2025年美国关税调整将为妇科肿瘤治疗领域带来许多复杂挑战，影响上游生产投入、跨境物流以及进口活性药物成分和医疗设备的经济效益。这些累积影响将波及供应商谈判、组件采购决策和紧急库存政策。为应对这些挑战，製造商正在评估替代供应商，探索区域性生产方案，并制定本地化的包装和标籤策略，以减轻关税带来的成本负担，同时确保产品品质和合规性。

细分市场观点：识别终端使用者环境、通路、给药途径、药物类别和癌症类型对药物取得和使用的影响

细分市场的趋势揭示了临床和商业职能部门在需求、应用和采购方面的不同驱动因素。基于终端用户细分，专科肿瘤诊所和门诊诊所往往优先考虑咨询时间短、可口服给药且患者支持服务更完善的治疗方法。同时，公立和私立医院则倾向于优先考虑住院患者的耐受性证据以及输液治疗方法的可近性。此外，专科护理中心作为创新中心，往往是标靶治疗和联合通讯协定早期应用的重点，从而影响当地的转诊模式以及与支付方的讨论。

美洲、欧洲、中东和非洲以及亚太地区的关键区域趋势将影响准入路线、监管立场和商业策略。

区域性洞察凸显了影响妇科肿瘤药物生命週期的不同监管、临床和商业环境。在美洲，多样化的支付模式和对创新报销机制的高度重视，推动了高成本疗法的适应性定价和按疗效付费合约的实施；同时，临床网络和专科肿瘤中心也促进了新型治疗方法的快速应用。跨境生产和分销结构也十分普遍，需要精心协调监管和物流，以确保供应的连续性。

公司层面的策略要务是协调研发、生产伙伴关係和商业能力，以确保临床应用和业务永续营运。

在企业层面，研发、供应链和商业营运的重点在于使其与不断变化的临床需求和支付方的期望保持一致。领先的製药和生物技术公司正在投资于整合分子诊断、真实世界数据和患者报告数据的证据平台，以加强核准申报和上市后提案主张。同时，创新开发商与契约製造组织 (CMO) 和区域生产商之间的策略合作伙伴关係也日益普遍，旨在降低供应风险并加速在地化上市。

为产业领导者提供切实可行的策略建议，重点在于证据产生、供应链多元化、分销优化和协作准入模式。

为了保持其在妇科肿瘤领域的优势，产业领导者应优先考虑整合策略。首先，他们应透过投资于超越关键性试验的实用证据生成项目，满足支付方和临床医生的资讯需求，这些项目应涵盖真实世界疗效、患者报告结局和卫生经济学模型。这将有助于建立引人注目的价值提案，从而支持药物获得优先上市资格并实现持续应用。

采用稳健的混合调查方法，整合临床证据、监管审查、专家访谈和供应链情境分析，为策略决策提供支援。

本分析的调查方法整合了同行评审的临床文献、监管指南、专家访谈和最佳实践，为相关人员建立了一个全面而实用的基础。临床见解源自于近期临床试验、指引更新和治疗层级发展的系统性回顾，而监管分析则纳入了与肿瘤药物和伴随诊断相关的最新政策声明和核准途径。为了使研究结果与实际营运限制和决策标准相符，研究人员也访问了肿瘤科医师、医院处方集管理人员、供应链负责人和支付方代表。

总之，我们强调，创新、可及性和运作韧性必须协调一致，才能在整个妇科肿瘤治疗过程中实现患者获益。

总体而言，妇科肿瘤领域正经历持续的策略调整阶段，其驱动力包括科学创新、支付方审查以及营运复杂性。标靶治疗和免疫疗法的进步有望显着改善众多患者的治疗效果，但实现这一目标需要严谨的证据、灵活的供应链以及能够适应不同医疗环境的商业模式。随着关税压力和区域监管趋势持续影响成本结构和产品上市顺序，相关人员必须采取灵活的策略，强调韧性、协作和以病人为中心的医疗服务。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • PARP抑制剂合併免疫疗法在卵巢癌一线治疗的临床应用
  • 扩大靶向叶酸受体α的抗体药物复合体在晚期子宫颈癌的应用
  • 口服选择性雌激素受体稳压器（SERDRs）的出现，为子宫内膜癌的个人化治疗提供了可能。
  • 真实世界数据支持在復发性卵巢癌患者中Bevacizumab维持治疗再挑战策略
  • 用于早期检测外阴部和阴道恶性肿瘤的预测性生物标记开发进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按最终用户分類的妇科癌症药物市场

  • 诊所
    • 肿瘤诊所
    • 门诊部
  • 医院
    • 私立医院
    • 公立医院
  • 专业医疗中心

9. 妇科癌症药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

10. 妇科癌症药物市场依给药途径划分

  • 腹腔内给药
  • 静脉注射
    • Bolus
    • 静脉注射
  • 口服
    • 胶囊
    • 药片

第十一章 妇科癌症药物市场（依药物类别划分）

  • 化疗药物
    • 烷化剂
    • 铂化合物
    • 紫杉烷类
  • 荷尔蒙疗法
    • 抗雌激素
    • Aromatase抑制剂
  • 免疫疗法
    • 查核点抑制剂
    • 疫苗
  • 标靶治疗
    • 血管新生抑制剂
    • PARP抑制剂
    • 蛋白酪氨酸激酶抑制剂

第十二章 妇科癌症药物市场（依癌症类型划分）

  • 子宫颈癌
  • 子宫内膜癌
  • 卵巢癌
  • 外阴癌

第十三章 妇科癌症药物市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 妇科肿瘤药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国妇科癌症药物市场概况

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Clovis Oncology, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Johnson & Johnson
    • Eisai Co., Ltd
    • Amgen Inc.
Product Code: MRR-DD0700E81D10

The Gynecological Cancer Drugs Market is projected to grow by USD 26.63 billion at a CAGR of 12.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.35 billion
Estimated Year [2025] USD 11.63 billion
Forecast Year [2032] USD 26.63 billion
CAGR (%) 12.53%

Authoritative introduction outlining the shifting gynecological oncology therapeutic landscape, clinical imperatives, innovation momentum, and stakeholder expectations

The contemporary landscape of gynecological oncology therapeutics is characterized by rapid scientific innovation, shifting regulatory priorities, and evolving care delivery models that collectively influence how treatments are developed, procured, and administered. Recent advances in targeted therapies, immuno-oncology agents, and more patient-friendly administration formats are reframing clinical decision-making, while health systems and payers increasingly emphasize value, real-world outcomes, and equitable access. Against this backdrop, stakeholders from clinical teams to supply chain managers must reconcile clinical efficacy with operational feasibility and reimbursement constraints.

In addition, patient expectations and advocacy have become central to the adoption curve for new treatments, prompting manufacturers and providers to invest in clearer evidence packages and patient support programs. As regulatory agencies refine accelerated pathways and post-market evidence requirements, sponsors must balance speed-to-market with robust safety and effectiveness data. Therefore, a holistic introduction to this environment clarifies the intersecting forces that will determine which therapies succeed in routine practice, how care pathways will be organized, and what capabilities institutions must develop to remain competitive and patient-centric.

Analysis of transformative shifts reshaping gynecological cancer drug development, commercial strategies, regulatory pathways, and clinical adoption

Transformative shifts in the gynecological oncology arena are driven by converging technological, clinical, and commercial trends that together alter development priorities and care delivery. Precision medicine has moved from concept to central practice, with genomic profiling and companion diagnostics guiding the selection of targeted therapies and PARP inhibitors, thereby redefining trial design and labeling strategies. Concurrently, immunotherapy experiences are informing combination regimens and maintenance approaches, which necessitate longer-term safety monitoring and novel endpoints. These scientific advances compel sponsors to pursue integrated development programs that anticipate regulatory evidence demands and real-world performance metrics.

On the commercial front, distribution strategies and patient access models are evolving to accommodate oral therapies and outpatient administration, reducing inpatient burden but increasing the complexity of adherence management and reimbursement navigation. Moreover, care settings such as specialty centers and oncology-focused clinics are amplifying their role in early adoption, while hospitals remain pivotal for complex infusions and inpatient care. Finally, manufacturers and service providers are rethinking supply chains and risk mitigation in response to geopolitical shifts and procurement reforms, leading to greater emphasis on resilience, multiple sourcing strategies, and digital tracking technologies. Together, these transformative shifts require coordinated action across R&D, medical affairs, market access, and supply-chain operations to translate innovation into measurable patient benefit.

Cumulative effects of United States tariffs in 2025 on supply chains, drug pricing, clinical access, and research activity within the gynecological oncology sector

United States tariff adjustments in 2025 introduce a consequential layer of complexity for gynecological oncology therapeutics, affecting upstream manufacturing inputs, cross-border logistics, and the economics of imported active pharmaceutical ingredients and devices. The cumulative effects reverberate through supplier negotiations, component sourcing decisions, and contingency stock policies. In response, manufacturers are assessing alternative suppliers, regional manufacturing options, and localized packaging and labeling strategies to mitigate tariff-driven cost exposure while preserving quality and regulatory compliance.

Patient access and provider procurement are also affected, since higher landed costs can translate into greater pressure on hospital formularies and distribution channels. Payers and procurement leads may intensify scrutiny of price-per-outcome and favor therapies with clearer value propositions or lower administration burdens. Additionally, clinical trial operations that depend on international supply lines for investigational products may face delays or increased overhead, prompting sponsors to pre-position inventory or qualify secondary suppliers. Policymakers and industry associations are likely to convene stakeholder dialogues to seek exemptions, provide clarifications, or design phased implementation measures that preserve access for essential oncology therapies. Overall, these tariff dynamics accelerate strategic shifts toward supply-chain diversification, onshoring where feasible, and enhanced collaboration between manufacturers and health systems to safeguard continuity of care.

Segmentation-focused perspective revealing how end-user settings, distribution channels, administration routes, drug classes, and cancer types influence adoption and procurement

Segment-specific dynamics reveal differentiated drivers of demand, adoption, and procurement across clinical and commercial functions. Based on end-user segmentation, clinics-distinguished between oncology-focused clinics and outpatient clinics-frequently prioritize therapies that enable shorter visits, oral administration, and robust patient support services, while hospitals, whether private or public, tend to emphasize evidence of inpatient tolerability and the availability of infusion-based regimens. Specialty centers, for their part, act as innovation hubs where early adoption of targeted therapies and combination protocols is often concentrated, influencing regional referral patterns and payer discussions.

When viewed through distribution channels, hospital pharmacies remain essential for infusion and inpatient therapies, online pharmacies are gaining traction for oral regimens and continuity-of-care supply, and retail pharmacies continue to serve as accessible touchpoints for maintenance therapies and supportive-care medications. Administration routes further refine adoption logic: intraperitoneal and intravenous options typically necessitate institutional infrastructure and nursing capacity, with intravenous treatments subdivided into bolus and infusion approaches that impose different scheduling and monitoring requirements; oral therapies, available as capsules or tablets, shift adherence and monitoring responsibilities towards outpatient care teams and digital adherence solutions.

Drug-class segmentation defines clinical positioning and lifecycle strategies. Chemotherapy agents, including alkylating agents, platinum compounds, and taxanes, remain central to many regimens but are increasingly complemented or replaced by hormonal therapies such as anti-estrogens and aromatase inhibitors for selected indications. Immunotherapy approaches-checkpoint inhibitors and therapeutic vaccines-introduce new safety and combination considerations, while targeted therapies such as angiogenesis inhibitors, PARP inhibitors, and tyrosine kinase inhibitors demand molecular diagnostics and refined patient selection. Finally, cancer-type segmentation across cervical, endometrial, ovarian, and vulvar cancers shapes clinical trial design, reimbursement narratives, and advocacy priorities, since each indication carries distinct natural history, screening pathways, and survivorship concerns. Taken together, these segmentation lenses guide tailored commercial models, clinical-support programs, and evidence-generation priorities that align with the operational realities of each channel and care setting.

Key regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways, regulatory positioning, and commercial strategy

Regional insights highlight distinct regulatory, clinical, and commercial environments that influence the lifecycle of gynecological oncology therapeutics. In the Americas, diverse payer models and a strong emphasis on innovative reimbursement mechanisms have encouraged adaptive pricing arrangements and outcomes-based contracting for high-cost therapies, while clinical networks and oncology centers of excellence drive rapid diffusion of new regimens. Cross-border manufacturing and distribution arrangements are also prevalent, necessitating careful regulatory harmonization and logistical coordination to ensure supply continuity.

Europe, the Middle East & Africa present a complex mosaic where centralized regulatory frameworks coexist with fragmented reimbursement rules across jurisdictions, prompting manufacturers to tailor submission strategies and real-world evidence plans region by region. In many countries within these regions, budget-constrained health systems prioritize cost-effectiveness and comparative effectiveness evidence, and public hospitals play a dominant role in high-intensity therapies. Additionally, access disparities persist across urban and rural areas, driving targeted access programs and collaborations with local health authorities.

Asia-Pacific is characterized by rapidly expanding clinical research capacity, growing domestic manufacturing capabilities, and heterogeneous payer landscapes that range from single-payer systems to private insurance models. Several markets in this region are accelerating regulatory reviews for oncology innovations and adopting digital health tools to support decentralized care and adherence monitoring. These regional differences collectively shape global launch sequencing, evidence-generation priorities, and partnership models that align with local clinical practice, procurement modalities, and patient-access imperatives.

Strategic company-level imperatives for aligning R&D, manufacturing partnerships, and commercial capabilities to secure clinical adoption and operational resilience

Company-level dynamics emphasize the need for firms to align R&D, supply chain, and commercial operations with evolving clinical needs and payer expectations. Leading pharmaceutical and biotech organizations are investing in integrated evidence platforms that combine molecular diagnostics, real-world outcomes, and patient-reported data to strengthen submissions and post-market value propositions. At the same time, strategic partnerships between innovative developers and contract manufacturing organizations or regional producers are becoming more common to mitigate supply risk and accelerate localized launches.

Commercially, firms are differentiating through service-oriented offerings such as patient-support programs, adherence solutions, and bundled care arrangements that reduce friction for clinicians and patients. Business development activity is concentrated on acquiring complementary portfolios-particularly targeted therapies, PARP inhibitors, and companion diagnostics-that can be rapidly positioned within existing oncology pathways. Additionally, some companies are experimenting with innovative contracting models and tiered pricing to preserve access across diverse payers while safeguarding long-term revenue sustainability. Operationally, investment in digital supply-chain visibility and serialization is increasingly seen as essential to maintain product integrity and comply with varied regional regulatory requirements. Collectively, these company insights underscore the importance of cross-functional alignment to convert scientific advances into durable clinical and commercial success.

Actionable strategic recommendations for industry leaders focused on evidence generation, supply-chain diversification, distribution tailoring, and collaborative access models

Industry leaders should prioritize integrated strategies that combine evidence generation, supply-chain resilience, and differentiated commercial models to stay ahead in gynecological oncology. First, invest in pragmatic evidence-generation programs that extend beyond pivotal trials to include real-world effectiveness, patient-reported outcomes, and health economic modeling to address payer and clinician information needs. By doing so, organizations can build compelling value propositions that support favorable formulary placement and durable uptake.

Second, diversify supply chains and pursue regional manufacturing options where feasible to reduce exposure to tariff and logistical shocks. Complementary to this, adopt advanced forecasting and inventory strategies that balance patient access with cost efficiency. Third, tailor distribution and patient-support models to administration routes and care settings: prioritize digital adherence tools and home-delivery solutions for oral therapies, while ensuring institutional readiness and training for complex infusion protocols. Fourth, cultivate strategic partnerships with diagnostics providers, academic centers, and advocacy groups to accelerate biomarker-driven adoption and to co-create patient-centric programs. Finally, embed flexible commercial contracting approaches, including outcomes-based arrangements and risk-sharing, to align stakeholder incentives and sustain access across heterogeneous payer environments. Taken together, these recommendations will help industry leaders translate scientific innovation into accessible, high-quality care for patients with gynecological cancers.

Robust mixed-methods research approach synthesizing clinical evidence, regulatory review, expert interviews, and supply-chain scenario analysis to inform strategic decisions

The research methodology underlying this analysis synthesizes peer-reviewed clinical literature, regulatory guidance, expert interviews, and operational best practices to create a comprehensive and pragmatic foundation for stakeholders. Clinical insights derive from a structured review of recent trials, guideline updates, and therapeutic class developments, while regulatory analysis incorporates recent policy statements and approval pathways relevant to oncology agents and companion diagnostics. Interviews with oncologists, hospital formulary managers, supply-chain leaders, and payer representatives were conducted to ground findings in real-world operational constraints and decision criteria.

Additionally, supply-chain and tariff impact assessments combine publicly available trade policy information with scenario-based operational modeling to identify likely stress points and mitigation pathways. Commercial and access perspectives were informed by case studies of recent launches and contracting innovations, with attention to administration route implications and channel readiness. Throughout, the methodology emphasized triangulation across data sources and stakeholder perspectives to ensure balanced, actionable insights that support both strategic planning and near-term operational decisions.

Concluding synthesis articulating how innovation, access, and operational resilience must be coordinated to realize patient benefits across gynecological oncology care pathways

In closing, the gynecological oncology therapeutics landscape is entering a sustained period of strategic realignment driven by scientific innovation, payer scrutiny, and operational complexity. Advances in targeted and immune-based therapies promise meaningful gains in outcomes for many patients, but realizing that promise requires rigorous evidence, adaptable supply chains, and commercial models aligned with diverse care settings. As tariff pressures and regional regulatory dynamics continue to influence cost structures and launch sequencing, stakeholders must adopt flexible strategies that emphasize resilience, collaboration, and patient-centered delivery.

Ultimately, organizations that integrate robust real-world evidence programs, diversify manufacturing and distribution, and deploy tailored access and adherence solutions will be best positioned to translate novel therapies into improved patient care. By focusing on cross-functional alignment and proactive stakeholder engagement, sponsors, providers, and payers can jointly optimize treatment pathways, improve access, and sustain innovation within gynecological oncology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical integration of PARP inhibitors with immunotherapy in front-line ovarian cancer management
  • 5.2. Expansion of antibody-drug conjugates targeting folate receptor alpha in advanced cervical cancer
  • 5.3. Emergence of oral selective estrogen receptor downregulators for personalized endometrial carcinoma therapy
  • 5.4. Real-world evidence supporting maintenance bevacizumab retreatment strategies in recurrent ovarian cancer patients
  • 5.5. Advances in predictive biomarker development for early detection of vulvar and vaginal malignancies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gynecological Cancer Drugs Market, by End User

  • 8.1. Clinics
    • 8.1.1. Oncology Clinics
    • 8.1.2. Outpatient Clinics
  • 8.2. Hospitals
    • 8.2.1. Private Hospitals
    • 8.2.2. Public Hospitals
  • 8.3. Specialty Centers

9. Gynecological Cancer Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Gynecological Cancer Drugs Market, by Administration Route

  • 10.1. Intraperitoneal
  • 10.2. Intravenous
    • 10.2.1. Bolus
    • 10.2.2. Infusion
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Tablet

11. Gynecological Cancer Drugs Market, by Drug Class

  • 11.1. Chemotherapy Agents
    • 11.1.1. Alkylating Agents
    • 11.1.2. Platinum Compounds
    • 11.1.3. Taxanes
  • 11.2. Hormonal Therapy
    • 11.2.1. Anti-Estrogens
    • 11.2.2. Aromatase Inhibitors
  • 11.3. Immunotherapy
    • 11.3.1. Checkpoint Inhibitors
    • 11.3.2. Vaccines
  • 11.4. Targeted Therapy
    • 11.4.1. Angiogenesis Inhibitors
    • 11.4.2. PARP Inhibitors
    • 11.4.3. Tyrosine Kinase Inhibitors

12. Gynecological Cancer Drugs Market, by Cancer Type

  • 12.1. Cervical Cancer
  • 12.2. Endometrial Cancer
  • 12.3. Ovarian Cancer
  • 12.4. Vulvar Cancer

13. Gynecological Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gynecological Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gynecological Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. AstraZeneca PLC
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. GlaxoSmithKline plc
    • 16.3.5. Clovis Oncology, Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Novartis AG
    • 16.3.8. Johnson & Johnson
    • 16.3.9. Eisai Co., Ltd
    • 16.3.10. Amgen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA GYNECOLO